Jun Zou
Jilin University
10 Papers
Jun Zou is an academic researcher from Jilin University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Generation of GGTA1-/-β2M-/-CIITA-/- Pigs Using CRISPR/Cas9 Technology to Alleviate Xenogeneic Immune Reactions
Rui Fu,Minghui Fang,Kai Xu,Jilong Ren,Jun Zou,Long Su,Xinxin Chen,PeiPei An,Dawei Yu,Meina Ka,Tang Hai,Ziyi Li,Wei Li,Yong-Guang Yang,Qi Zhou,Zheng Hu +15 more
TL;DR: It is demonstrated that elimination of GGTA1, β2M, and CIITA genes in pigs can effectively alleviate xenogeneic immune responses and prolong pig organ survival in xenogenesis and will facilitate future research in xenotransplantation.
40
Upregulation of SLAMF3 on human T cells is induced by palmitic acid through the STAT5-PI3K/Akt pathway and features the chronic inflammatory profiles of type 2 diabetes.
Tong Zhou,Guixia Wang,Yanan Lyu,Lei Wang,Siyao Zuo,Jun Zou,Lin Sun,Wenjie Zhao,Chang Shu,Yong-Guang Yang,Zheng Hu +10 more
TL;DR: This work found a significant upregulation of signaling lymphocytic activation molecule family member 3 (SLAMF3) expression on T cells from T2D patients compared to those of healthy controls, and found that this upregulation was associated with an increased ability to produce proinflammatory cytokines.
Complement Depletion Improves Human Red Blood Cell Reconstitution in Immunodeficient Mice
Bing Chen,Wei Fan,Jun Zou,Si-wen Zhang,Jin He,Chang Shu,Guoqing Zhao,Tianmeng Sun,Zheng Hu,Yong-Guang Yang +9 more
TL;DR: Data indicate that complement, which might be dispensable for hRBC rejection by macrophages, is critical in hR BC rejection by other types of murine phagocytic cells, such as neutrophils and endothelial cells.
21
Posttransplant blockade of CXCR4 improves leukemia complete remission rates and donor stem cell engraftment without aggravating GVHD.
Long Su,Minghui Fang,Jun Zou,Sujun Gao,Xiao-Yi Gu,Xian-Di Meng,Xue Wang,Zheng Hu,Yong-Guang Yang +8 more
TL;DR: The authors showed that post-transplant treatment with the CXCR4 antagonist AMD3100 significantly improved the eradication of leukemia cells in the BM in PDX mice grafted with B-ALL cells from multiple patients.
8
Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies
Tian-Tian Ji,Shuaishuai Niu,Minghui Fang,Xin Wang,Jun Zou,Fei Xu,Jun Wu,Lei Wang,Zhikun Li,Yong-Guang Yang,Jie Hao,Wei Li,Zheng Hu,Qi Zhou +13 more
TL;DR: Wang et al. as discussed by the authors used selective genetic editing of human leucocyte antigen (HLA) molecules to generate HESCs with immunocompatibility for the Chinese population.
4